Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8235-8251

  Dupouy, Sandra ^a   Doan, Van Kien ^a   Wu, Zherui ^a,b   Mourra, Najat ^a   Liu, Jin ^b   de Wever, Olivier ^c   Llorca, Frédérique Penault ^d   Cayre, Anne ^d   Kouchkar, Amal ^e   Gompel, Anne ^b   Forgez, Patricia ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d CENTRE JEAN PERRIN   (France)

^e Centre Pierre et Marie Curie   (Algeria)

Author keywords

Cancer growth and metastasis; EGF like ligands; EGFR; HER2; HER3; Neurotensin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GELATINASE B; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LAPATINIB; MECLINERTANT; METFORMIN; NEU DIFFERENTIATION FACTOR; NEUREGULIN 2; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; NEUROTENSIN TYPE 1 RECEPTOR; QUINAZOLINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; BREAST TUMOR; CELL ACTIVATION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR GROWTH; ANIMAL; BREAST NEOPLASMS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ADULT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; MCF-7 CELLS; METFORMIN; MIDDLE AGED; NEOPLASM INVASIVENESS; NEUROTENSIN; QUINAZOLINES; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, NEUROTENSIN; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908005765     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1632     Document Type: Article

References (51)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J.Clin. 2011; 61:69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J.Clin. 2013; 63:11-30.
3. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur.J.Cancer. 2008; 44: 2806-2812.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235:177-182.
5. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J.Clin.Oncol. 2010; 28:1138-1144.
6. Giltnane JM, Moeder CB, Camp RL, Rimm DL. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer. 2009; 115:2400-2409.
7. Spears M, Taylor KJ, Munro AF, Cunningham CA, Mallon EA, Twelves CJ, Cameron DA, Thomas J, Bartlett JM. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res.Treat. 2012; 132: 463-470.
8. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J.Natl.Cancer Inst. 2013; 105: 266-273.
9. Valachis A, Nearchou A, Lind P, Mauri D. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence. Breast Cancer Res.Treat. 2012; 135:655-662.
10. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004; 5:317-328.
11. Dupouy S, Mourra N, Doan VK, Gompel A, Alifano M, Forgez P. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie. 2011; 93:1369-1378.
12. Wu Z, Martinez-Fong D, Tredaniel J, Forgez P. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. Front Endocrinol.(Lausanne). 2012; 3.
13. Melander O, Maisel AS, Almgren P, Manjer J, Belting M, Hedblad B, Engstrom G, Kilger U, Nilsson P, Bergmann A, Orho-Melander M. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA. 2012; 308:1469-1475.
14. Dupouy S, Viardot-Foucault V, Alifano M, Souaze F, Plu-Bureau , Chaouat M, Lavaur A, Hugol D, Gespach C, Gompel A, Forgez P. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS.One. 2009; 4:e4223.
15. Somai S, Gompel A, Rostene W, Forgez P. Neurotensin counteracts apoptosis in breast cancer cells. Biochem.Biophys.Res.Commun. 2002; 295:482-488.
16. Souaze F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, Gompel A, Forgez P. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res. 2006; 66:6243-6249.
17. Rosell S, Thor K, Rokaeus A, Nyquist O, Lewenhaupt A, Kager L, Folkers K. Plasma concentration of neurotensin-like immunoreactivity (NTLI) and lower esophageal sphincter (LES) pressure in man following infusion of (Gln4)-neurotensin. Acta Physiol Scand. 1980; 109: 369-375.
18. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J.Biol.Chem. 1973; 248:6854-6861.
19. Reinecke M. Neurotensin. Immunohistochemical localization in central and peripheral nervous system and in endocrine cells and its functional role as neurotransmitter and endocrine hormone. Prog.Histochem.Cytochem. 1985; 16:1-172.
20. White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, Gvozdenovic-Jeremic J, Shah P, Shiloach J, Tate CG, Grisshammer R. Structure of the agonist-bound neurotensin receptor. Nature. 2012; 490:508-513.
21. Amorino GP, Deeble PD, Parsons SJ. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene. 2007; 26: 745-756.
22. Zhao D, Zhan Y, Zeng H, Koon HW, Moyer MP, Pothoulakis C. Neurotensin stimulates expression of early growth response gene-1 and EGF receptor through MAP kinase activation in human colonic epithelial cells. Int.J.Cancer. 2007; 120:1652-1656.
23. Muller KM, Tveteraas IH, Aasrum M, Odegard J, Dawood M, Dajani O, Christoffersen T, Sandnes DL. Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. BMC.Cancer. 2011; 11.
24. Mei ZB, Zhang ZJ, Liu CY, Liu Y, Cui A, Liang ZL, Wang GH, Cui L. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS.ONE. 2014; 9:e91818.
25. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009; 69:6539-6545.
26. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS.One. 2013; 8:e57289.
27. Alifano M, Souaze F, Dupouy S, Camilleri-Broet S, Younes M, hmed-Zaid SM, Takahashi T, Cancellieri A, Damiani S, Boaron M, Broet P, Miller LD, Gespach C, Regnard JF, Forgez P. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin.Cancer Res. 2010; 16:4401-4410.
28. Hasegawa K, Carr BI. Neurotensin-amplification of DNA synthesis stimulated by EGF or TGF alpha in primary cultures of adult rat hepatocytes. Cell Struct.Funct. 1993; 18:105-110.
29. Olsen DA, Bechmann T, Ostergaard B, Wamberg PA, Jakobsen EH, Brandslund I. Increased concentrations of growth factors and activation of the EGFR system in breast cancer. Clin.Chem.Lab Med. 2012; 50:1809-1818.
30. Wiley HS. Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system. J.Cell Biol. 1988; 107:801-810.
31. Jiang X, Sorkin A. Epidermal growth factor receptor internalization through clathrin-coated pits requires Cbl RING finger and proline-rich domains but not receptor polyubiquitylation. Traffic. 2003; 4:529-543.
32. Beguinot L, Lyall RM, Willingham MC, Pastan I. Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc.Natl.Acad.Sci.U.S.A. 1984; 81:2384-2388.
33. Stoscheck CM, Carpenter G. Characterization of the metabolic turnover of epidermal growth factor receptor protein in A-431 cells. J.Cell Physiol. 1984; 120: 296-302.
34. Wang Z, Zhang L, Yeung TK, Chen X. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol.Biol.Cell. 1999; 10:1621-1636.
35. Kornilova ES, Taverna D, Hoeck W, Hynes NE. Surface expression of erbB-2 protein is post-transcriptionally regulated in mammary epithelial cells by epidermal growth factor and by the culture density. Oncogene. 1992; 7: 511-519.
36. Haslekas C, Breen K, Pedersen KW, Johannessen LE, Stang E, Madshus IH. The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Mol.Biol.Cell. 2005; 16:5832-5842.
37. Hartman Z, Zhao H, Agazie YM. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Oncogene. 2013; 32:4169-4180.
38. Offterdinger M, Bastiaens PI. Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane. Traffic. 2008; 9:147-155.
39. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J.Biol.Chem. 1999; 274:8865-8874.
40. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J.Biol.Chem. 1996; 271:5251-5257.
41. Waterman H, Alroy I, Strano S, Seger R, Yarden Y. The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J. 1999; 18:3348-3358.
42. Waterman H, Sabanai I, Geiger B, Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J.Biol.Chem. 1998; 273: 13819-13827.
43. Marshall C, Blackburn E, Clark M, Humphreys S, Gullick WJ. Neuregulins 1-4 are expressed in the cytoplasm or nuclei of ductal carcinoma (in situ) of the human breast. Breast Cancer Res.Treat. 2006; 96:163-168.
44. Dunn M, Sinha P, Campbell R, Blackburn E, Levinson N, Rampaul R, Bates T, Humphreys S, Gullick WJ. Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer. J.Pathol. 2004; 203:672-680.
45. Klubo-Gwiezdzinska J, Jensen K, Costello J, Patel A, Hoperia V, Bauer A, Burman KD, Wartofsky L, Vasko V. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr.Relat Cancer. 2012; 19:447-456.
46. Toy-Miou-Leong M, Cortes CL, Beaudet A, Rostene W, Forgez P. Receptor trafficking via the perinuclear recycling compartment accompanied by cell division is necessary for permanent neurotensin cell sensitization and leads to chronic mitogen-activated protein kinase activation. J.Biol.Chem. 2004; 279:12636-12646.
47. Dupouy S, Mourra N, Doan VK, Gompel A, Alifano M, Forgez P. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie. 2011; 93:1369-1378.
48. De Wever O, Hendrix A, De BA, Westbroek W, Braems G, Emami S, Sabbah M, Gespach C, Bracke M. Modeling and quantification of cancer cell invasion through collagen type I matrices. Int.J.Dev.Biol. 2010; 54:887-896.
49. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979; 18: 5294-5299.
50. Souaze F, Rostene W, Forgez P. Neurotensin agonist induces differential regulation of neurotensin receptor mRNA. Identification of distinct transcriptional and post-transcriptional mechanisms. J.Biol.Chem. 1997; 272:10087-10094.
51. Younes M, Dupouy S, Wu Z, Lupo AM, Mourra N, Takahashi T, Flejou J, Trédaniel J, Régnard JF, Damotte D, Alifano M, Forgez P. Oncotarget.2014; in press.